

Electronic Acknowledgement Receipt

EFS ID:	1991143
Application Number:	10598840
International Application Number:	
Confirmation Number:	1117
Title of Invention:	3-Heterocyclyl-4-Phenyl-Triazole Derivatives as Inhibitors of the Vasopressin Via Receptor
First Named Inventor/Applicant Name:	Justin S Bryans
Customer Number:	28523
Filer:	John Anthony Wichtowski/Madeline Deveran
Filer Authorized By:	John Anthony Wichtowski
Attorney Docket Number:	PC32229A
Receipt Date:	19-JUL-2007
Filing Date:	18-MAY-2007
Time Stamp:	17:21:48
Application Type:	U.S. National Stage under 35 USC 371

Payment information:

Submitted with Payment	yes
Payment was successfully received in RAM	\$ 180
RAM confirmation Number	2001
Deposit Account	161445

The Director of the USPTO is hereby authorized to charge indicated fees and credit any overpayment as follows:
Charge any Additional Fees required under 37 C.F.R. Section 1.16 and 1.17

File Listing:

Document Number	Document Description	File Name	File Size(Bytes) /Message Digest	Multi Part /.zip	Pages (if appl.)
1	Foreign Reference	WO2002010166.pdf	2808581	no	105
			167133c7b5c4808304add6f1d3d3d4e3221e028d		
Warnings:					
Information:					
2	Foreign Reference	WO2002028858.pdf	2814308	no	102
			1cc7ed39412c4c5ebd322354ba3b16269145d1		
Warnings:					
Information:					
3	Foreign Reference	WO2002028859.pdf	2512176	no	106
			8d4330e61d332c4b968501e40019750c02cd2f23a		
Warnings:					
Information:					
4	Foreign Reference	WO2002028865.pdf	2381221	no	95
			fe5af25d5d668a5c0c99778d3488567dab821408b		
Warnings:					
Information:					
5	Foreign Reference	WO2002036593.pdf	1907400	no	66
			e124eece56baf622316ab3771b0c38072bc0c9		
Warnings:					
Information:					
6	Foreign Reference	WO2002038563.pdf	2265160	no	81
			64d18efb031eb6cd0b4e54b01bbe793c2bd0e33		
Warnings:					
Information:					
7	Foreign Reference	WO2003000691.pdf	1495403	no	56
			3ba66c5b457d5a21b19f9d4189523ae71d772e91b		
Warnings:					
Information:					
8	NPL Documents	COCO-AmFamilyPhys-1999.pdf	1426713	no	9
			9067d5e15f17451ca3344da1777e2f764dc35c13		
Warnings:					
Information:					
9	NPL Documents	Fininin-JPharmSci-1999.pdf	989564	no	4
			532b216d7995a0cbb7c767676bdcfa1459947ba83		

Warnings:					
Information:					
10	NPL Documents	Haleblian-JPharmSci1975.pdf	4599159 08b1324f1ec31d74f8b2c0cf1ab1f89ba44030e19	no	20
Warnings:					
Information:					
11	NPL Documents	Liang-ExpertOpinion981-2001.pdf	1447318 2640850067a2a992b9a485bec0960353d40099127	no	6
Warnings:					
Information:					
12	NPL Documents	Lieberman-PharmDosageVol1-1980.pdf	990695 147507096e0fa28d1ae778bc3a94d599d870c62d	no	79
Warnings:					
Information:					
13	NPL Documents	Schroeder-PedClinicsNA-1999.pdf	851366 50eecc0901d925439fa31c4e3c09a291a399477a	no	14
Warnings:					
Information:					
14	NPL Documents	Verma-PharmTechOnLine-2001.pdf	3541326 65962111bc5c93f5e025da503d51cc1e1989760c	no	14
Warnings:					
Information:					
15	NPL Documents	Wenk-EuropJPharma-2003.pdf	200567 25b6124e5d9f42a35c23bc0e2f22aeb4c260d716	no	6
Warnings:					
Information:					
16	Information Disclosure Statement (IDS) Filed	iPC32229A-IDS.PDF	373074 17854ab39d9c7bc099455610dc620325dc10e	no	6
Warnings:					
Information:					
This is not an USPTO supplied IDS fillable form					
17	NPL Documents	BANWELL-JofOrgChem--2002.pdf	992740 096786176c33e9f9cc02733b6f7a392ba31e825ea97	no	4
Warnings:					
Information:					

18	NPL Documents	Carter-ExpertOpinTherapeuti cPatents--1998-1997.pdf	1322484 2367770111eeb049e420652786359ad 04e6192	no	9
Warnings:					
Information:					
19	NPL Documents	Falch-EurJMedChem--1991. pdf	1553445 03b3dea020149f54ca76b147b75930 e9531a05	no	9
Warnings:					
Information:					
20	NPL Documents	Rotella-JMedChem--2000.pd f	1545700 b7211aaa860c3096ca76595c25c03b 60c29a3a	no	7
Warnings:					
Information:					
21	Fee Worksheet (PTO-06)	fee-info.pdf	8246 0d5e115d33af94abc16d057a87b5c64 d29305e	no	2
Warnings:					
Information:					
Total Files Size (in bytes):			36026646		
<p>This Acknowledgement Receipt evidences receipt on the noted date by the USPTO of the indicated documents, characterized by the applicant, and including page counts, where applicable. It serves as evidence of receipt similar to a Post Card, as described in MPEP 503.</p> <p><u>New Applications Under 35 U.S.C. 111</u> If a new application is being filed and the application includes the necessary components for a filing date (see 37 CFR 1.53(b)-(d) and MPEP 506), a Filing Receipt (37 CFR 1.54) will be issued in due course and the date shown on this Acknowledgement Receipt will establish the filing date of the application.</p> <p><u>National Stage of an International Application under 35 U.S.C. 371</u> If a timely submission to enter the national stage of an international application is compliant with the conditions of 35 U.S.C. 371 and other applicable requirements a Form PCT/DO/EO/903 indicating acceptance of the application as a national stage submission under 35 U.S.C. 371 will be issued in addition to the Filing Receipt, in due course.</p> <p><u>New International Application Filed with the USPTO as a Receiving Office</u> If a new international application is being filed and the international application includes the necessary components for an international filing date (see PCT Article 11 and MPEP 1810), a Notification of the International Application Number and of the International Filing Date (Form PCT/RO/105) will be issued in due course, subject to prescriptions concerning national security, and the date shown on this Acknowledgement Receipt will establish the international filing date of the application.</p>					